1 Clinical
assessments were also made, which included Positive and Negat
2 Retinal imaging and clinical
assessments were carried out in 7411 participants.
3 y 7, and micro-computed tomography (micro-CT) and histology
assessments were carried out on day 28.
4 Pharmacodynamic
assessments were Cogstate cognitive tests and electrophysiolo
5 Follow-up
assessments were completed at 3 months post-injury.
6 Organizational
assessments were completed at sites once before and 4 times a
7 Six-month
assessments were completed by 258 participants (129 intervent
8 Cognitive performance
assessments were completed by 5,972 and 4,939 respondents at
9 All
assessments were completed by independent evaluators masked t
10 Enrollment occurred between November 2013 and July 2017;
assessments were completed by the end of February 2018.
11 RAI
assessments were completed on 36,261 unique patients presenti
12 Follow-up
assessments were conducted 1, 3, 6, and 12 months after traum
13 Field-based
assessments were conducted across 255 plots covering undistur
14 Laboratory
assessments were conducted after the Brucella events to ident
15 Patient
assessments were conducted at least 2 days (5 +/- 2 d) after
16 Assessments were conducted before and immediately after parti
17 Final dental
assessments were conducted by a single examiner visiting 189
18 Shelter
assessments were conducted concurrently at a convenience samp
19 and Intrauterine Growth Restriction cohort, multiple serial
assessments were conducted over the course of pregnancy to qu
20 from the USEPA non-cancer risk assessments and cancer risk
assessments were developed for some of these VOCs.
21 Assessments were done on the second day and at 3 months: endo
22 Subjective symptom
assessments were estimated lowlier than objective finding ass
23 Tumor
assessments were evaluated by investigators per immune-relate
24 The posttransplant
assessments were from period prevalent, rather than incident,
25 Bioaccessible/dialyzable fractions based exposure
assessments were highlighted the overestimation of exposures
26 carcinoma at nine LT centers in the United States with LFI
assessments were included.
27 Assessments were made after 6 months of storage.
28 advanced blast simulator was used to expose rats to BOP and
assessments were made to identify structural and molecular ch
29 Postoperative
assessments were masked to the allocated intervention.
30 eactogenicity assessments or blood draws for immunogenicity
assessments were masked.
31 Serial parent proxy-report health-related quality of life
assessments were obtained at baseline, 7 days, and 1, 3, 6, a
32 Safety, efficacy, and functionality
assessments were performed at 3, 6, and 12 months post implan
33 Assessments were performed at the baseline (week 0), week 4,
34 Other
assessments were performed at week 0 and week 8.
35 Stereological analyses and remodeling
assessments were performed by histology.
36 Neurocognitive
assessments were performed during therapy and during 1 year o
37 Before and after home monitoring, 2 VF
assessments were performed in clinic using standard automated
38 In-person rheumatological
assessments were performed on selected, available patients.
39 Safety
assessments were performed through week 18.
40 Shear wave elastography
assessments were performed using a Toshiba Aplio 500 version
41 Quality
assessments were performed using the Joanna Briggs Institute
42 Standard safety
assessments were performed.
43 d noninvasive (NI) biventricular contractile, and metabolic
assessments were performed.
44 Several functional and subjective gait
assessments were performed.
45 re gestational week 12, and three-dimensional breast volume
assessments were performed.
46 Primary outcome
assessments were planned at post-treatment, 12 months post-ba
47 Pharmacodynamic
assessments were repeated 1 to 6 months thereafter.
48 and specificity ranged from 85% to 97% when LR-TR equivocal
assessments were treated as nonviable.
49 When LR-TR equivocal
assessments were treated as viable, sensitivity of tumor necr
50 Clinical
assessments were undertaken at baseline and follow-up (median